垃圾，6000多就没_老虎社区_美港股上老虎 - 老虎社区

2
2
收藏

王老_涨
2021-08-23

垃圾，6000多就没了

暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购

8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。公开发售阶段先瑞达医疗获约654.51倍认购，

暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

2

举报

评论（2）

推荐
最新

夜袭女儿国
·2021-08-23
这个时间还敢打新哈哈哈，你那真有钱
回复
点赞
举报
价值投机投资
·2021-08-23
利息不是钱啊[捂脸]
回复
点赞
举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":835844020,"tweetId":"835844020","gmtCreate":1629707005160,"gmtModify":1629707005160,"author":{"id":3576968461524729,"idStr":"3576968461524729","authorId":3576968461524729,"authorIdStr":"3576968461524729","name":"王老_涨","avatar":"https://static.tigerbbs.com/1cdae70773b784525bd2cae07e5777f1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>垃圾，6000多就没了</p></body></html>","htmlText":"<html><head></head><body><p>垃圾，6000多就没了</p></body></html>","text":"垃圾，6000多就没了","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/835844020","repostId":1183822547,"repostType":4,"repost":{"id":"1183822547","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706678,"share":"https://www.laohu8.com/m/news/1183822547?lang=&edition=full","pubTime":"2021-08-23 16:17","market":"hk","language":"zh","title":"暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1183822547","media":"老虎资讯综合","summary":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，","content":"<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n暗盘：先瑞达医疗-B跌超26%，此前获逾654倍认购\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-08-23 16:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>8月23日消息，<a href=\"https://laohu8.com/S/06669\">先瑞达医疗-B</a>暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。</p>\n<p><img src=\"https://static.tigerbbs.com/518a125cb15d68545d7248ded8786752\" tg-width=\"1080\" tg-height=\"2250\" referrerpolicy=\"no-referrer\"></p>\n<p>公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。</p>\n<p>此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：</p>\n<p><img src=\"https://static.tigerbbs.com/11a4aa099d57c3457eaf96f7ae36b32f\" tg-width=\"697\" tg-height=\"584\" referrerpolicy=\"no-referrer\"></p>\n<p>甲组每手1000股，一手中签率3%，认购200手稳中一手。</p>\n<p>乙组门槛为25万股（1250手），获配2000股（2手）。<img src=\"https://static.tigerbbs.com/740152f2007693f65f5e418d5cdb7062\" tg-width=\"735\" tg-height=\"782\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/92f44c14a652c527f2da790c4c93f0a4\" tg-width=\"771\" tg-height=\"778\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n<p></p>\n<p>所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。</p>\n<p>据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。</p>\n<p>财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"06669":"先瑞达医疗-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183822547","content_text":"8月23日消息，先瑞达医疗-B暗盘报17.5港元，较发行价跌26.47%。公司每股定价23.8港元，每手1000股，将于8月24日（周二）港股上市。\n\n公开发售阶段先瑞达医疗获约654.51倍认购，分配至公开发售的发售股份最终数目为3431.8万股，占发售股份总数的约50%（任何超额配股权获行使前）。合共接获310661份有效申请，一手中签率3%，认购200手稳中一手。\n此外，国际发售已获超额认购，发售股份最终数目为3431.5万股，相当于发售股份总数的约50%（任何超额配股权获行使前）。老虎资讯整理相关数据如下表：\n\n甲组每手1000股，一手中签率3%，认购200手稳中一手。\n乙组门槛为25万股（1250手），获配2000股（2手）。\n\n\n所得款项净额约15.29亿港元将用作以下用途：32%将被分配给核心产品；23%将分配给现有产品管线中余下的24款产品；7%用于扩大生产能力及强化制造能力；24%用于通过内部研发、合作、合并及收购、授权引进或股权投资等方式扩大公司产品组合；8%拨作营运资金及一般企业用途；6%拨作偿还贷款。\n据悉，先瑞达医疗是一家领先的中国创新医疗器械企业，专注于提供血管疾病的「介入无植入」治疗方案。截至最后实际可行日期，公司已有四款产品实现商业化，产品管线涵盖24款处于不同开发阶段的在研产品。\n财务数据方面，公司于PTA球囊及DCB产品推出后开始产生收益。于2019年、2020年及2021年前三个月，公司录得收益人民币1.25亿元、1.94亿元及5332万元，同期录得净利润人民币2310.5万元、-4429.2万元及-4001.6万元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1352,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":5621449,"commentId":"5621449","gmtCreate":1629720953180,"gmtModify":1629720953180,"authorId":3556430317654104,"author":{"id":3556430317654104,"idStr":"3556430317654104","authorId":3556430317654104,"name":"夜袭女儿国","avatar":"https://static.tigerbbs.com/981270b89fc3d1572f9537a8e19c6c9c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835844020,"objectIdStr":"835844020","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"这个时间还敢打新哈哈哈，你那真有钱","text":"这个时间还敢打新哈哈哈，你那真有钱","html":"这个时间还敢打新哈哈哈，你那真有钱","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":5619821,"commentId":"5619821","gmtCreate":1629708207988,"gmtModify":1629708207988,"authorId":3457141092286042,"author":{"id":3457141092286042,"idStr":"3457141092286042","authorId":3457141092286042,"name":"价值投机投资","avatar":"https://static.tigerbbs.com/be23b46444ac2a96142fb1b29256fc15","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.26","exceedPercentage":"80.31%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835844020,"objectIdStr":"835844020","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"利息不是钱啊[捂脸]","text":"利息不是钱啊[捂脸]","html":"利息不是钱啊[捂脸]","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}